Drugs / JNJ-64565111
JNJ-64565111
Trials 17 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 111 trials | ||||||
| Phase 1 | NCT06701305 | Jun 2024 → Feb 2025 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT06052566 | Nov 2023 → Dec 2024 | metabolic dysfunction-associated steatohepatitis | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT06836037 | Sep 2022 → Feb 2023 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT03618160 | Aug 2018 → Jun 2019 | — | Janssen Pharmaceutical K.K. | Terminated | No outcome recorded |
| Phase 1 | NCT03606057 | Jul 2018 → Feb 2019 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT03586843 | Jun 2018 → Mar 2019 | obesity disorder | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT03546205 | Jun → Dec 2018 | chronic renal failure syndrome | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT03235219 | Aug 2017 → Feb 2018 | type 2 diabetes mellitus | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT02862431 | Jul → Nov 2016 | type 2 diabetes mellitus | Janssen Research & Development, LLC | Terminated | No outcome recorded |
| Phase 1 | NCT01373450 | Jun → Jul 2011 | type 2 diabetes mellitus | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT01055340 | Apr → May 2010 | obesity disorder | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 26 trials | ||||||
| Phase 2 | NCT06482112 | Jul 2024 → Jun 2025 | NAFLD1 | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 2 | NCT06465186 | Jul 2024 → Aug 2026 overdue | NAFLD1, metabolic dysfunction-associated steatohepatitis | Merck Sharp & Dohme LLC | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05877547 | Jun 2023 → Dec 2025 | NAFLD1, metabolic dysfunction-associated steatohepatitis | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 2 | NCT04944992 | Aug 2021 → Oct 2022 | NAFLD1, metabolic dysfunction-associated steatohepatitis | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 2 | NCT03586830 | Jun 2018 → Apr 2019 | type 2 diabetes mellitus | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 2 | NCT03486392 | Mar 2018 → Mar 2019 | obesity disorder | Janssen Research & Development, LLC | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 18 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JNJ-64565111 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03486392 ↗ |
| Known as | Efinopegdutide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06836037 ↗ |
| Known as | OXM | “Oxyntomodulin (OXM), an enteroendocrine hormone, causes appetite suppression, increased energy expenditure, and weight loss in obese humans via activation of GLP-1 and glucagon...” PMID 29545266 ↗ Mar 2018 |
| Known as | Oxyntomodulin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01373450 ↗ |
| Action | Activate | “via activation of GLP-1 and glucagon receptors” PMID 29545266 ↗ Mar 2018 |
| Route | Intravenous | “Single infusion of OXM 3.0 pmol/kg/min by IV” NCT01055340 ↗ |